RT Journal
A1 Bollu M, Marte-Grau AC, Bobba RK
T1 5-α reductase inhibitors and risk of hip fracture
JF JAMA
JO JAMA
YR 2009
FD March 4
VO 301
IS 9
SP 935
OP 935
DO 10.1001/jama.2009.182
UL http://dx.doi.org/10.1001/jama.2009.182
AB 
It would also be interesting to know if the patients with hip fractures had been using long-term steroids, were smokers, used alcohol, had epilepsy, or had prior hip fractures, because these are associated with fracture incidence. We would also like to know if any of the patients with hip fractures had been screened for osteoporosis after the index event of the fracture. The study by Jacobsen et al recruited patients from 1997 to 2006, and during this period the updated American Urological Association guidelines2 were released, recommending the use of 5-α reductase inhibitors over surgical intervention for treatment of benign prostatic hypertrophy with hematuria; this may have increased the total number of patients being treated with 5-α reductase inhibitors.